Kane Biotech (CVE:KNE) Shares Down 20% – What’s Next?

Kane Biotech Inc. (CVE:KNE) shares traded down 20% during mid-day trading on Tuesday . The company traded as low as C$0.02 and last traded at C$0.02. 132,200 shares were traded during mid-day trading, a decline of 23% from the average session volume of 171,277 shares. The stock had previously closed at C$0.03.

Kane Biotech Stock Down 20.0%

The company has a market cap of C$4.10 million, a P/E ratio of -1.00 and a beta of 1.08. The stock has a 50-day moving average of C$0.03 and a two-hundred day moving average of C$0.03. The company has a debt-to-equity ratio of -197.52, a quick ratio of 0.39 and a current ratio of 0.61.

Kane Biotech Company Profile

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.